Efficacy of tezepelumab in patients with severe, uncontrolled asthma and low blood eosinophil counts not receiving maintenance oral corticosteroids
A. Menzies-Gow (London, United Kingdom), B. Cook (Gaithersburg, MD, United States), G. Colice (Gaithersburg, MD, United States), Å. Hellqvist (Gothenburg, Sweden), J. Llanos-Ackert (Thousand Oaks, CA, United States), C. Ambrose (Gaithersburg, MD, United States)
Source: International Congress 2022 – Recent advances in biological treatments for asthma
Session: Recent advances in biological treatments for asthma
Session type: Oral Presentation
Number: 3670
   
Rating: 
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
A. Menzies-Gow (London, United Kingdom), B. Cook (Gaithersburg, MD, United States), G. Colice (Gaithersburg, MD, United States), Å. Hellqvist (Gothenburg, Sweden), J. Llanos-Ackert (Thousand Oaks, CA, United States), C. Ambrose (Gaithersburg, MD, United States). Efficacy of tezepelumab in patients with severe, uncontrolled asthma and low blood eosinophil counts not receiving maintenance oral corticosteroids. 3670
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
|
|